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important safety test. Subsequently, we investigated the clearance of this improved vaccine strain following 23 vaccination and found a more effective innate immune control over the sapM::Tn vaccine bacteria as 24 compared to WT BCG. This leads to a fast contraction of IFNγ producing Th1 and Tc1 cells after sapM::Tn BCG 25 vaccination. These findings corroborate that a live attenuated vaccine that affords improved long-term 26 survival upon TB infection can be obtained by a mutation that further attenuates BCG. These findings suggest 27 that an analysis of the effectiveness of innate immune control of the vaccine bacteria could be instructive 28 also for other live attenuated TB vaccines that are currently under development, and encourage further 29 studies of SapM mutation as a strategy in developing a more protective live attenuated TB vaccine. 30 1. Introduction 33 Today, TB remains one of the major causes of infectious disease and death throughout the world [1] . About 34 10 million people developed TB in 2017, with an estimated 1.3 million deaths. 35
Although new and promising anti-tubercular drugs are in or approaching the clinic, full control over this 36 devastating disease will necessarily require a good, preventive anti-TB vaccine [2] . M. bovis Bacille-Calmette-37 Guérin (BCG) is the only licensed vaccine today, and already in use for almost 100 years. Although BCG is 38 protective against TB meningitis and disseminated TB in children, its efficacy against pulmonary TB is highly 39 variable and not sufficient for disease control [3] [4] [5] . 40
Currently, 13 vaccine candidates are under active development and in the process of clinical testing. Besides 41 two live recombinant candidates (VPM1002 and MTBVAC) which are being tested to replace BCG as a priming 42 vaccine, the candidates being mainly variations of booster vaccines with recurrent key mycobacterial 43 antigens [2, 6, 7] . Several of these vaccine candidates yield enhanced interferon γ (IFNɣ)-producing cellular 44 immunity and enhanced control over bacterial replication in the first weeks after TB challenge in animal 45 models. However, reports that show extended long-term survival of vaccinated animals upon TB challenge 46 are much rarer. In the category of priming vaccines, it has been shown that rBCG30 (BCG Tice overexpressing 47 the M. tb 30-kDa major secretory protein antigen 85B)-immunized mice survive longer than BCG-immunized 48 mice following TB challenge [8] . SO2 (phoP inactivated in M. tb strain MT103), the MTBVAC (containing a 49 double deletion in phoP and fadD26) prototype, conferred greater efficacy than BCG in a high-dose challenge, 50 long-term survival experiment in guinea pigs, while no difference to WT BCG was observed after low-dose 51 challenge [9] . The recombinant BCG strain AFRO-1 (BCG1331 ΔureC::ΩpfoAG137Q, Ag85A, Ag85B and TB10.4) 52 affords better protection than BCG in mice following aerosol challenge with Mycobacterium tuberculosis 53 (M.tb) [10] . Additionally, some prime-boost vaccination strategies demonstrated improved long-term 54 survival of M.tb-challenged guinea pigs versus BCG alone: BCG priming followed by the M72 recombinant 55 protein booster vaccine (fusion of Mtb32 and Mtb39 antigens of Mtb) [11] and ID93 (combines four antigens 56 6 infection, rather than the protracted chronic infection caused by the current BCG vaccine, may yield an 81 immune status that affords more prolonged control of a subsequent TB infection. 82 The M. bovis BCG Pasteur strain 1721, used to create the sapM::Tn BCG mutant strain [13, 25] , differs from 86 the 1173P2 Pasteur vaccine strain by a K43R point mutation in the rpsL gene, conferring streptomycine 87 resistance [26] , which is useful to avoid contaminations during the lengthy and involved procedures in 88 ordered transposon mutant library production. To investigate whether there are any additional variants 89 between the WT BCG Pasteur and the sapM::Tn BCG mutant, we performed a whole-genome resequencing 90 analysis on both strains (paired end 2 x 150 bp), mapping to the M. bovis BCG Pasteur 1173P reference 91 genome, resulting in ± 80x average coverage of mapped reads (Suppl. Fig. 1 ). We could reconfirm the location 92 of the inserted Himar1 transposon, at the TA dinucleotide 8 bp before the sapM start codon (Fig. 1) . This was 93 also demonstrated by de novo assembly of the sequencing reads from the sapM::Tn BCG mutant (data not 94 shown). In addition, we performed a probabilistic variant analysis on both WT BCG and sapM::Tn BCG 95 mappings and detected only minor modifications (single amino acid change) with unknown impact. These 96 variants are listed in Table 1 and were verified by Sanger sequencing. All variants versus the Pasteur reference 97 are present in both the parental as well as the sapM::Tn strains, with only one exception, i.e. the frameshift 98 mutation in the sugI gene, coding for sugar-transport integral membrane protein. This mutation probably 99 arose after the library preparation (in a later passage of the strain), since this frameshift mutation is not 100 present in sapM::Tn. The exact function of sugI is unknown, however, it shows distant sequence similarity to 101 glucose permease GlcP of S. coelicolor and the galactose (GalP) and arabinose (AraE) transporters of E. coli. 102 Thus, the system is likely to transport a monosaccharide [27] . It is described to be non-essential in the H37Rv 103 strain [28] , which explains the absence of phenotype in WT BCG due to the frameshift mutation. The SNV in 104 sapM::Tn BCG SugI also likely arose after library preparation since it is not present in WT BCG. Hence, sugI 105 appears to be a highly variable gene in the BCG lineage during in vitro cultivation, as the three strains each 106 have a different sequence variant. Interestingly, both the parental as well as the sapM::Tn strain contain a 107 frame-shift mutation in the gene coding for FadD26, a key enzyme in the biosynthesis pathway of the 108 phthiocerol dimycocerosate (PDIM) class of virulence lipids. This fadD26 mutation is interesting from a 109 vaccine engineering point-of-view, as it further attenuates virulence [29, 30] . 110
Results

Transposon-induced transcriptional effects 111
Transcriptome analysis, by both RNAseq analysis and RT-PCR, demonstrated that the sapM transcript is ~20-112 50-fold reduced compared to the WT BCG, while the transcription levels of other genes remain largely 113 unchanged (< 2-fold change), except for a ~10-fold upregulation of upp (encoding uracil 114 phosphoribosyltransferase) which is immediately upstream of sapM in the genome, and a modest 2.4-fold 115 downregulation of its downstream gene (BCG_3376) ( Fig. 2A -C, Suppl. Fig. 2A -B, Suppl. Table 1 ). A few (~6) 116 other genes show a differential expression pattern (~2-fold change) between WT BCG and sapM::Tn, 117 however, this effect is marginal compared to the differences in expression of sapM and upp. The transposon 118 insertion thus only majorly affects one nearby gene, and the changes in sapM and upp transcription have 119 almost no secondary effects on overall transcriptional regulation. According to the Operon Correlation 120
Browser on the TB Database [31] , the gene coding for SapM in M. tb (Rv3310) and the downstream gene 121 Rv3311 potentially form an operon. However, in M. bovis BCG we see that transposon disruption of the sapM 122 upstream region in sapM::Tn BCG very strongly reduces the levels of sapM transcript, while having a much 123 more modest effect on the levels of BCG_3376 (Rv3311 ortholog) transcription. These data indicate that both 124 genes are likely differentially regulated, questioning the idea of an operonic structure. 125 2.1.3 SapM protein is undetectable and secreted total phosphatase activity is strongly reduced 126
As the SapM protein contains a 43 AA N-terminal signal sequence and thus gets secreted in the culture 127 medium, we collected culture supernatant samples at various time-points. 128
First, we performed an ELISA on these supernatant samples with a newly generated antibody directed against 129 the recombinant SapM protein produced in E. coli (Fig. 2D ). While the amount of SapM protein steadily 130 increases over time of culture in the WT BCG, the signal is nearly absent in the sapM::Tn BCG mutant samples 131 for all time-points. We further confirmed the absence of full-length SapM protein in the sapM::Tn BCG strain 132 by SDS-PAGE and western blotting in an independent experiment ( Fig. 2E ). We detected a band of ± 28 kDa 133 in the WT BCG, but not in the sapM::Tn BCG mutant sample. A smear is also detected above the 28 kDa band, 134 which likely represents aspecific binding (as the pattern appears to be identical for all samples). To check for 135 any remaining phosphatase activity in the culture medium, we performed an in vitro phosphatase assay with 136 p-Nitrophenyl phosphate (pNPP) as a substrate [32] (Fig. 2F ). The measured in vitro activity is significantly 137 reduced for the sapM::Tn BCG mutant sample compared to WT BCG at early time-points. At later time-points 138 (day 8), we still observe a considerable signal, which is expected, as the assay would also pick up activity of 139 other phosphatases such as the protein tyrosine phosphatases (PtpA and PtpB) [33] . 140
Consequently, based on all of the data on this vaccine strain, we concluded at this point that its improved 141 vaccine efficiency must indeed be due to a loss of function of SapM or the upregulation of upp transcription, 142 or both. BCG mutant compared to WT BCG in vivo, we investigated bacterial virulence in the absence of adaptive 149 immunity. Immunocompromised SCID mice, lacking both T and B cells, were infected intravenously (i.v.) with 150 a high (3x10 7 CFU) or lower dose (3x10 6 CFU) of both strains and survival was monitored ( Fig. 3 ). After both 151 low and high doses, SCID mice infected with sapM::Tn BCG mutant showed similar survival to mice infected 152 with WT BCG. Thus, in the SCID model, virulence of sapM::Tn BCG is comparable to WT BCG. 153 2.3 At the lymph node draining the vaccination site, the sapM::Tn BCG mutant is controlled faster than 154 the WT BCG strain 155 Our previously reported observations indicated that vaccination with the sapM::Tn BCG mutant triggered 156 more effective recruitment of iDCs into the draining lymph nodes (LNs) in Balb/c mice [13] . This lead us to 157 study the influence of this more effective induction of the innate immune response at early time points after 158 sapM::Tn BCG vaccination on the fate of the vaccine inoculum. To enhance the validity, experiments were 159 performed in F1 mice (C57BL/6J x Balb/c) to assess robustness of the observed effects to a more 160 heterogeneous immunogenetic background [34] . After subcutaneous (s.c) vaccination of F1 mice, less 161 bacteria (~50%) were recovered from LNs of sapM::Tn BCG infected mice as compared to WT BCG-infected 162 mice at all time-points analyzed (i.e. days 8, 14 and 28 post-infection) ( Fig. 4A ). It is clear that whereas WT 163 BCG could amplify from the inoculum, this was barely the case for the sapM::Tn BCG mutant. Since 164 differences are clear already 8 days post-vaccination, this result is most consistent with improved control by 165 innate immune mechanisms. Indeed, an analysis of intracellular survival of WT BCG and sapM::Tn BCG upon 166 infection of bone marrow derived macrophages (BM-DMs), showed that WT BCG and sapM::Tn BCG are 167 taken up similarly (as shown before [13] ) but that growth of the sapM::Tn BCG mutant is better controlled 168 compared to the WT BCG strain upon infection (Fig. 4B ). In line with these findings, such improved clearance 169 of SapM-mutated M.tb by BM-DMs has recently also been described [16] , an effect that was attributed to 170 improved phagosomal maturation. 171
To further evaluate the impact of early innate growth control of the bacteria, we have analyzed survival of 172 sapM::Tn BCG and WT BCG after intravenous infection of F1 mice. Twenty-four hours post-infection, the 173 bacterial load in the lungs and spleens from mice that were infected with WT BCG was higher than the loads 174 of those infected with the sapM::Tn BCG mutant (~50%) ( Fig. 4C ). Three weeks post-infection, the difference 175 was still observed in the lungs, but not in the spleens. Similar results were obtained in the spleen of C57BL/6J 176 mice, but not in the lungs (Suppl. Fig. 3A ). Cytokine levels were analyzed in the serum of i.v. exposed mice at 177 different time-points (6h, 24h, 48h post-vaccination), and significantly higher levels of IL1-β and IL17 could 178 be measured 24h post-sapM::Tn BCG vaccination compared to WT BCG vaccination (Suppl. Fig. 3B ). In view 179 of this early time point post-vaccination, both IL1-β and IL17 are produced by innate immune cells. These 180 particular cytokines are known to be important innate cytokines for bacterial killing, particularly in 181 mycobacterial infection [35, 36] , which is consistent with the reduced sapM::Tn BCG bacterial load. 182 2.4 Complementation of the sapM::Tn mutation reverses the phenotypes. We then further analyzed how improved innate control over vaccine bacteria changes the immune response 197 to the vaccine. Hereto, we have vaccinated C57BL/6J mice s.c. with WT BCG or sapM::Tn BCG mutant. At 198 different time points, mice were sacrificed and LNs and spleens were isolated. DC phenotyping was 199 performed. Significant differences were observed in total leukocyte numbers and iDC recruitment kinetics 200 after sapM::Tn BCG versus WT BCG vaccination. In general, we observe a faster induction of the innate 201 immune response, reflected by a faster recruitment of innate inflammatory cells to the secondary lymphoid 202 organs (dLN-spleen), and by a faster contraction of the innate immune response, seen by lower leukocyte 203 cell numbers at day 14 post-vaccination with BCG sapM::Tn BCG ( Fig. 7) . Next, T cell immunity was assessed 204 by restimulation of splenocytes or LN cells with either the mycobacterial antigen Ag85A, the M.tb extract 205 PPD or by anti-CD3/28, a stimulus that activates all T cells, as a control. Vaccination with sapM::Tn BCG leads 206 to a lower number of lymph node and spleen IFNγ-producing CD4 + (Th1) and CD8 + (Tc1) T cells 2 weeks post-207 vaccination compared to WT BCG ( Fig. 8A ). After vaccination with a lower dose, this observation is only seen 208 for Tc1 cells, following polyclonal stimulation in the LNs and spleen (Suppl. Fig. 4 ). IFNγ measurements in the 209 supernatant following stimulation with the different antigens also demonstrated lower levels of IFNγ in the 210 sapM::Tn BCG condition (Fig. 8B ). These lower numbers of IFNγ-producing CD4 + and CD8 + T cells were seen 211 at early time points (2 weeks post-infection), but the difference became non-significant at later time points 212 (Suppl. Fig. 5 ), consistent with the hypothesis that a fast innate control of bacterial load results in a swift 213 contraction of the TB-specific Th1 and Tc1 cellular response after sapM::Tn BCG vaccination. The sapM::Tn 214 BCG vaccine thus behaves like a rapidly (though not completely) controlled bacterial infection, contrary to 215 WT BCG, which expands and causes a more protracted infection at the vaccination site. 216 Chen et al. compared PDIM/PGL production in 12 different M. bovis BCG substrains and found that while 230 most were PDIM-positive (including BCG Pasteur), three of these strains, BCG Japan (or Tokyo), Moreau and 231 Glaxo, do not produce this class of lipids [38] . The authors further reported that there was a correlation 232 between the virulence that was associated with the BCG substrains and their lipid profile: the on average 233 more virulent, PDIMs/PGLs-producers and the on average less virulent, PDIMs/PGLs non-producers. In a later 234 study it was shown that the PDIM-defect in BCG Moreau was due to a deletion in the FadD26 and the directly 235 downstream ppsA gene in the same operon, which is also involved in the PDIM/PGL lipid biosynthesis 236 pathway [39] . The authors reported that this locus was intact in BCG Japan and Glaxo. Naka et al later showed 237 that BCG Tokyo 172 is actually divided into two subpopulations, in which type II, but not type I, has a 238 frameshift mutation in the ppsA gene and thus does not produce PDIM lipids [40] . It is unclear whether this 239 strain is the same as the Japan strain that was earlier reported to lack PDIMs [38] . As the Japan/Tokyo, 240
Discussion
Moreau and Glaxo substrains are not derived from one another [41] , and as we have here detected a fadD26 241 frameshift in a substrain derived from BCG Pasteur, these independent mutations in genes coding for key 242 enzymes in the PDIM/PGL lipid biosynthesis pathway indicate that there may be a selective force in favor of 243 losing this class of lipids during in vitro BCG cultivation. We also conclude that, as our strain has this 244 background fadD26 mutation, the sapM::Tn vaccine strain in our studies is in fact a fadD26/sapM::Tn double 245 mutant, which is important knowledge for further development, as it shows that the sapM mutation 246 improves vaccine efficacy even in this fadD26 background, as is currently being used for safety enhancement 247 of the MTBVAC lead clinical TB vaccine candidate. In addition to our sapM::Tn BCG mutant, this FadD26 248 mutation will almost certainly also be present in the Zmp1 BCG mutant candidate vaccine that was described 249 in [42], since it is also derived from the M. bovis BCG Pasteur 1721 strain. 250
By comparative transcriptome profiling between WT BCG and sapM::Tn BCG, we observed an almost 251 complete absence of sapM transcript in the mutant strain, together with a significant upregulation of sapM's 252 upstream gene upp. By RNAseq analysis, we further showed that the global transcriptional landscape in the 253 sapM::Tn BCG mutant strain is not significantly altered compared to the WT BCG. 254
The most promising strategy for improved TB vaccines currently is the development of an improved 255 attenuated live vaccine, either used alone or in combination with subunit booster vaccines [6] . Furthermore, 256 re-vaccination with BCG in adolescence has recently shown promise as well [43] . An improved version of the 257 BCG vaccine could thus be valuable in this context too. However, working with live vaccines encompasses 258 potential safety issues, especially since a high incidence of HIV is found in areas where TB is endemic. A novel 259 vaccine candidate should therefore be at least as safe as BCG. Safety of the sapM::Tn BCG strain was tested 260 in immunocompromised SCID mice, in comparison with the WT BCG. Survival time upon infection of the mice 261 was similar for both strains, at both high and low infectious doses, demonstrating comparable safety of the 262 sapM::Tn BCG strain and WT BCG. 263
Due to the lack of natural infection-induced protection, the type of immune response that is crucial in 264 preventing M.tb infection and TB, and which therefore should be induced by vaccination, remains largely 265 unknown. At present, it is believed that a particular balance between differentially polarized adaptive 266 immune responses is crucial to overcome a TB infection. M. tb as well as M. bovis, from which BCG derives, 267 have evolved immunomodulatory mechanisms to perturb this balance to its own benefit [44,45]. We and 268 others propose that an improved, live attenuated vaccine will need to be engineered to take down these 269 immunomodulatory virulence factors from the pathogenic parental Mycobacteria from which these vaccines 270 (incl. BCG) have been derived, and we propose that the SapM secreted phosphatase is such a factor. Our were frozen as 1 mL cultures at OD600 1 in 20% glycerol (final concentration). For all in vitro and in vivo 297 infections described in this paper, cells were started from a glycerol stock, grown in shaking culture flasks 298 (OD600 always ≤1) as described above, subcultured once and further grown until OD600~0.8 after which cells 299 were collected and prepared for infection. For each experiment, we confirmed that we immunized with the 300 same number of viable CFU by CFU plating of the inoculum. prep and sequencing was performed by the VIB Nucleomics Core facility (www.nucleomics.be). The data was 306 analyzed by the VIB Nucleomics Core facility and the VIB Bioinformatics Core facility (www.bits.vib.be) using 307 CLC Genomics Workbench (CLC-GWB [48], http://www.clcbio.com/products/clc-genomics-workbench/). All 308 reads were processed using the standard CLC-GWB settings. The reads from the sapM::Tn BCG strain were 309 used for de-novo assembly in order to locate the inserted transposon. To this end, the phiMycoMarT7 310 transposon sequence (GenBank AF411123.1) was blasted against all de-novo contigs (n = 201). Using this 311 information, a modified reference sequence was built from the M. bovis BCG Pasteur str. 1173P2 reference 312 (NCBI NC_008769.1) by introducing the phiMycoMar T7 transposon sequence. All reads from both strains 313
were then mapped to their corresponding reference sequences using the CLC-GWB default command 314 settings (mismatch cost 2, insertion cost 3, deletion cost 3, length fraction 0.5, similarity fraction 0.8). A 315 probabilistic variant analysis as implemented in the CLC-Genomics Workbench package [48] was then 316 performed (min coverage 10, 90% variant probability) to obtain the variants listed in Table 1 . 317
To confirm these variants, PCR primers were designed flanking the mutations, after which the regions were 318 amplified (Phusion polymerase), purified (AMPure XP beads) and Sanger sequenced (VIB Genetics Service 319 Facility (http://www.vibgeneticservicefacility.be) with nested primers (see table below). PCR conditions were 320 as follows: 98°C for 3 minutes; 25 cycles of denaturation (98°C for 20 seconds), annealing (69°C for 20 321 seconds) and extension (72°C for 1 minute); 72°C for 5 minutes. The primer details are given in Suppl. Table  322 2. 323 4.3 RT-qPCR analysis 324 10 mL of M. bovis BCG cultures (grown in standard 7H9 medium until an OD600 of 0.8 -1.0) were centrifuged 325 and the pellets were washed once with 0.5% Tween80 solution in PBS. The pellet was then resuspended in 326 500 µl of RLT buffer (RNeasy Mini Kit, Qiagen; supplemented with β-ME). The cells were disrupted with glass 327 beads in Retsch MM2000 bead beater at 4°C in screw-cap tubes (pre-baked at 150°C). After centrifugation (2 328 min, 13,000 rpm, 4°C), the supernatant was transferred to a fresh eppendorf tube. To recover the lysate 329 trapped in between the beads, 800 µl of chloroform was added to the beads and centrifuged, after which the 330 upper phase was transferred to the same eppendorf tube as before. Then, 1 volume of Acid 331 Phenol/Chloroform (Ambion) was added, incubated for 2 minutes and centrifuged (5 min, 13,000 rpm, 4°C). 332
The upper aqueous phase was transferred to a fresh eppendorf tube and this last step was repeated once. 333
An equal volume of 70% ethanol was added and the sample was transferred to an RNeasy spin column 334 (RNeasy Mini Kit, Qiagen). The kit manufacturer's instructions were followed to purify the RNA. with the Prism 6 software package using a two-tailed t-test. Primer details are given in Suppl. triplicates until an OD600 of 0.8 -1.0 and RNA was prepared as described for the RT-qPCR analysis. This RNA 353 was then depleted of ribosomal RNA (Ribo-Zero rRNA removal kit for gram-positive bacteria) and the 354 remaining RNA was prepared for Illumina sequencing (TruSeq stranded total RNA preparation kit). This library 355 preparation takes into account the strandedness of the RNA and is able to distinguish between sense and 356 antisense transcripts. The libraries were sequenced on an Illumina NextSeq500 (75 bp single-end). The library 357 preparation and sequencing was performed by the VIB Nucleomics Core facility (www.nucleomics.be). The 358 data was analyzed using the standard RNA-seq analysis workflow in CLC Genomics Workbench v7 (CLC-GWB 359
[48], http://www.clcbio.com/products/clc-genomics-workbench/). In short, raw sequencing reads were 360 quality trimmed and mapped to the reference genome (M. bovis BCG Pasteur str. 1173P2), taking into 361 account the read directionality. The total number of unique reads per gene (averaged over the triplicate 362 samples) of both the WT BCG and the sapM::Tn BCG strain were then compared using the EdgeR statistical 363 test [50, 51] . 364
Recombinant SapM production and anti-SapM antibody preparation 365
To express SapM in E. coli, we constructed an expression vector pLSPelB-SapM mature-His, being pLSAH36 366 carrying a PelB signal sequence, mature SapM without signal sequence and a C-terminal His tag. This was 367 transformed to the E. Coli BL21+pICA2 expression strain. E. coli was grown in LB medium supplemented with 368 ampicillin and kanamycin at 28°C. Expression was induced with 1 mM IPTG overnight (ON) at 18°C. Bacteria 369 were centrifuged and the pellet was sonicated in sonication buffer (50 mM Tris, 100 mM NaCl, 1 mM PMSF, 370 pH8). After centrifugation at 18000 rpm for 1h, supernatant was removed and inclusion bodies were 371 extracted in extraction buffer (20 mM NaH2PO4, 0,5 M NaCl, 5 mM β-mercaptoethanol, 6 M guanidine 372 hydrochloride, 5 mM imidazole, pH 7.5) ON at 4°C. Denatured protein was purified using nickel sepharose 373 and eluted in elution buffer (20 mM NaH2PO4, 50 mM NaCl, 5 mM β-mercaptoethanol, 8 M guanidine 374 hydrochloride, 400 mM imidazole, pH 7.5) and a final desalting was performed on a sephadex G25. The 375 purification was performed by the VIB Protein Core facility. The rabbit polyclonal anti-SapM antibody was 376 generated by immunization of 2 rabbits (CER groupe, Belgium) with purified SapM protein (625µg/mL, in the 377 text named anti-SapM; denatured, full-length protein produced in E. coli as described above). Immunizations 378 and bleedings were done following the standard CER protocol. In brief, rabbits were subcutaneously injected 379 on days 0, 14, 28 and 56 with 500µL antigen/500µL adjuvant. Bleedings were performed on day 0 380 (preimmune 2mL), day 38 (small test sample 2mL), day 66 (large bleed 20+2mL) and day 80 (final bleeding). 381
Sample from the final bleeding of rabbit 2 is used in the experiments described here. The rabbit polyclonal 382 anti-SapM-C-term antibody (Anti-PepC) was raised against a synthetic C-terminal peptide (peptide synthesis 383 (CYATNAPPITDIWGD, terminal modification: amidation (C-terminal) and conjugation to KLH) and 384 immunizations performed by GenScript). Immunizations and bleedings were done following the standard 385 GenScript protocol. In brief, 2 rabbits were subcutaneously injected on days 0 and day 14. First bleedings 386 were performed on day 0 (pre-immune, 2mL) and 21 (1mL). A third immunization was performed on day 35. 387
A second bleeding was done on day 42 (1mL). A fourth immunization was done on day 56. Final bleeding was 388 done on day 63. Only pre-immune serum and final anti-sera was provided by Genscript. SapM protein) were diluted 1:2 in 100 mM of carbonate buffer (3.03 g of Na2CO3 and 6 g of NaHCO3 in 1 L of 405 water; pH 9.6) and coated on 96-well maxisorp plates (Nunc) (overnight at 4°C). The plate was then washed 406 three times with PBST (PBS + 0.05% Tween-20). The plate was blocked with 1% of BSA in PBS (2 hours at room 407 temperature (RT)). After plate washing, the rabbit polyclonal anti-SapM or anti-PepC antibody was added 408 (diluted 1:5000 in PBS with 0.1% Tween-20 and 0.1% goat serum) (1 hour at RT). After washing, the plate was 409 incubated with the secondary HRP-labeled donkey anti-rabbit antibody (GE healthcare) (diluted 1:5000 in 410 PBS with 1% BSA) (1 hour at RT). After washing, 100 µl of the TMB substrate was added to the plate (Becton 411 Dickinson), incubated at RT for 30 minutes, after which 50 µl of 2N H2SO4 was added to stop the reaction. 412
The optical density at 450 nm was then determined with a bio-rad plate reader (wavelength correction at 413 655 nm). LNs were removed aseptically and homogenized in PBS-0.5% Tween 20 + EDTA-free complete protease 448 inhibitor (Roche). Neat, 1/10, 1/100 and 1/1000 dilutions were made of which 50µL was plated in duplicate 449 on 7H10-OADC agar and the colonies were counted after 21 days. The CFU counts were calculated from the 450 highest dilution showing distinct colonies. 451
In another experiment, at the age of 8 weeks, female C57BL/6J x Balb/c (F1, Harlan) mice were infected 452 intravenously (i.v.) with 2x10 6 CFU WT BCG or sapM::Tn BCG mutant in 200 µl of PBS. At 24h and 3 weeks 453 post-infection, 8 mice/group were sacrificed; spleens and lungs were removed aseptically, homogenized in 454 PBS-0.5% Tween 20 + EDTA-free complete protease inhibitor (Roche) and analyzed for CFU counts as above. 455
Again, neat, 1/10, 1/100 and 1/1000 (lung) and neat, 1/10, 1/100, 1/1000, 1/10 000, 1/100 000 (spleen) 456 dilutions were made of which 50µL was plated in duplicate on 7H10-OADC agar. Additionally, 6h, 24h and 457 48h post-infection, blood was taken retro-orbitally and collected in BD microtainer SST tubes for serum 458 preparation, which was frozen at -20°C until assay. Serum cytokines were determined by bioplex (BioPlex Pro 459 Cytokine Express Assay, Biorad). 460
In at third experiment, at the age of 8 weeks, female C57BL/6J (Janvier) mice were infected s.c. (at the base 461 of the tail) with 2x10 6 CFU WT BCG or sapM::Tn BCG mutant in 100 µl PBS. At day7, 14 and 28 post-infection, 462 6 mice/group were sacrificed; inguinal and brachial LNs were removed aseptically and analyzed for CFU 463 counts as above. XbaI and ApaLI and the integrative vector pMV306Kan (kindly provided by Prof. W.R. Jacobs jr.) was digested 471 with NheI and ApaLI, after which the appropriate fragments were purified from gel and ligated together to 472 form pMV306HygSapMoperon, an integrating vector with the SapM operon (Plasmid map in Suppl. Fig. 7) . 473
The plasmid pMV306HygSapMoperon was electroporated into the sapM::Tn BCG mutant strain [53] . 474
Hygromycin resistant colonies were selected and surviving clones were tested on a phosphatase assay. Table 3 and gating strategy is given in Suppl. Fig. 8 . Results are presented as means ± standard error of the mean (SEM) unless otherwise stated and groups 518 were compared using statistical tests as mentioned in the text, using Prism Software (GraphPad Software, 519 San Diego, CA). 520 * Not verified by Sanger sequencing, because the mutation is synonymous ** Sequencing did not work, due to the presence of repeats in the region of the mutation Table 1 Illumina resequencing Sanger analysis
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